News – Page 740 – Endpoints News

With stars aligned and cash in reserve, Bob Nelsen's Resilience plans a makeover at 2 new facility additions to its ...

5 years ago

'Never been more urgent:' Scynexis looks to tackle superbug crisis with late-stage readout for antifungal hopeful

5 years ago

A spotlight schizophrenia drug in Neurocrine's $2B Takeda deal flunks its first major test. But it's not giving up ...

5 years ago

Mesoblast gets a $110M lifeline from SurgCenter Development; uniQure still unsure if gene therapy spurred cancer ...

5 years ago

After bailing on Covid-19 vaccines, Merck will team up with J&J to produce its shot as part of unusual Big Pharma ...

5 years ago

AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab

5 years ago

The next big biotech superstar? Paul Sekhri has some thoughts on that

5 years ago

A 'love story': WuXi AppTec wraps UK-based CRO into its cell and gene therapy unit

5 years ago

FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK

5 years ago

How we are staying connected when we’re apart

5 years ago

Covid-19 roundup: AstraZeneca ships first COVAX doses as Canada recommends against 65+ use; Inovio, still stuck in ...

5 years ago

Introducing Endpoints FDA+, our new premium weekly regulatory news report led by Zachary Brennan

5 years ago

Publisher's note

Merck pulls Keytruda in SCLC after accelerated nod. Is the FDA getting tough on drugmakers that don't hit their ...

5 years ago

OrbiMed, biopharma's biggest investor, closes $3.5B in three new private funds

5 years ago

Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria

5 years ago

Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street

5 years ago

Merck gets a PDUFA date for its chronic cough contender; Morphic shares skyrocket on the heels of PhI data rollout in ...

5 years ago

Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the ...

5 years ago

With new $106M crossover round, Tenaya preps heart failure programs for the clinic — and maybe an IPO

5 years ago

Biotech's shares routed after the FDA demands new trial, raises safety and endpoint issues in surprise CRL

5 years ago

Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

5 years ago

BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder

5 years ago

Angling Pfizer, AstraZeneca jumps into commercial PD-(L)1 fight in China

5 years ago

Merck KGaA earmarks $855M for Debiopharm's programmed cell death promoting drug in global licensing deal

5 years ago

First page Previous page 737 738 739740741 742 743 Next page Last page